Life Science Compliance Update 340B and You: Thoughts on Program Oversight for Pharmaceutical… Thomas Sullivan Apr 14, 2017 0 The 340B Drug Discount Program plays an important role in the United States healthcare system by providing healthcare services…
Congress McCaskill Opens Investigation into Opioid Manufacturers Thomas Sullivan Apr 13, 2017 0 Senator Claire McCaskill, Ranking Member of the Senate’s Homeland Security and Governmental Affairs Committee, has launched a…
Congress President Trump Meets with Democrats on Drug Prices Thomas Sullivan Apr 13, 2017 0 President Donald Trump recently met with several Democratic lawmakers regarding rising drug prices, including Representative…
Affordable Care Act AHCA Failed…Now What? Thomas Sullivan Apr 12, 2017 0 Moments before a scheduled vote on the bill, Republican House leaders announced that they were pulling the American Health Care…
Congress Senate Holds Confirmation Hearing on Gottlieb Thomas Sullivan Apr 11, 2017 0 On April 5, 2017, the Senate Health, Education, Labor, and Pensions (HELP) Committee held a confirmation hearing on the nomination…
CMS Open Payments Starts Review and Dispute…On A Saturday Thomas Sullivan Apr 11, 2017 0 With the close of Open Payments submission just behind us, the Centers for Medicare & Medicaid Services (CMS) plans to publish…
Innovation Modern Drug Development Thomas Sullivan Apr 10, 2017 0 In an article published in Science Translation Medicine, Disciplined approach to drug discovery and early development, Robert…
Anti Kickback The New Strict French Anti-Bribery Law Thomas Sullivan Apr 7, 2017 0 In early December 2016, the Sapin II law was enacted in France. The law, which is meant to promote transparency, fight against…
GAO Senators Ask GAO to Investigate Potential Orphan Drug Act Abuse Thomas Sullivan Apr 6, 2017 0 In a March 3, 2017, letter to the United States Government Accountability Office, Senators Orrin Hatch, Chuck Grassley, and Tom…
FDA OPDP Picks Up Steam on Enforcement Letters Thomas Sullivan Apr 5, 2017 0 After a fairly slow 2016, the United States Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP)…